Literature DB >> 22840317

Expression of KITENIN and its association with tumor progression in oral squamous cell carcinoma.

Tae Mi Yoon1, Sun-Ae Kim, Joon Kyoo Lee, Young-Lan Park, Gyu Yeol Kim, Young-Eun Joo, Jae Hyuk Lee, Kyung Keun Kim, Sang Chul Lim.   

Abstract

OBJECTIVE: KAI1 COOH-terminal interacting tetraspanin (KITENIN) contributes to tumor invasion and metastasis in various cancers. The aim of this study was to investigate expression of KITENIN in patients with oral cavity squamous cell carcinoma (SCC) and to determine whether KITENIN affects tumor cell behavior in oral cavity SCC cell line.
METHODS: Western blotting and immunohistochemistry was used to assess alteration of KITENIN expression in human oral cavity SCC and normal oral cavity mucosa. To evaluate the impact of KITENIN knockdown, the cell invasion assay and cell migration assay using small-interfering RNA were performed.
RESULTS: KITENIN protein expression was significantly increased in human oral cavity SCC tissues than in normal oral cavity mucosa by Western blotting. KITENIN immunoreactivity was strongly identified in human oral cavity SCC relative to adjacent normal tissue. Knockdown of KITENIN resulted in significantly reduced cell invasion in human oral cavity SCC cells (p=0.001). Cell migration showed a marked decrease in KITENIN knockdown oral cavity SCC cells compared to the negative control oral cavity SCC cells (p=0.01).
CONCLUSION: KITENIN is associated with tumor invasiveness and metastasis in human oral cavity SCC.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22840317     DOI: 10.1016/j.anl.2012.07.006

Source DB:  PubMed          Journal:  Auris Nasus Larynx        ISSN: 0385-8146            Impact factor:   1.863


  7 in total

1.  Genomic Characterization of Esophageal Squamous Cell Carcinoma Reveals Critical Genes Underlying Tumorigenesis and Poor Prognosis.

Authors:  Hai-De Qin; Xiao-Yu Liao; Yuan-Bin Chen; Shao-Yi Huang; Wen-Qiong Xue; Fang-Fang Li; Xiao-Song Ge; De-Qing Liu; Qiuyin Cai; Jirong Long; Xi-Zhao Li; Ye-Zhu Hu; Shao-Dan Zhang; Lan-Jun Zhang; Benjamin Lehrman; Alan F Scott; Dongxin Lin; Yi-Xin Zeng; Yin Yao Shugart; Wei-Hua Jia
Journal:  Am J Hum Genet       Date:  2016-04-07       Impact factor: 11.025

Review 2.  Vangl1 and Vangl2: planar cell polarity components with a developing role in cancer.

Authors:  Jason Hatakeyama; Jessica H Wald; Ignat Printsev; Hsin-Yi Henry Ho; Kermit L Carraway
Journal:  Endocr Relat Cancer       Date:  2014-06-30       Impact factor: 5.678

3.  Downregulation of VANGL1 inhibits cellular invasion rather than cell motility in hepatocellular carcinoma cells without stimulation.

Authors:  Gokhan Ozan Cetin; Asli Toylu; Nese Atabey; Zeynep Sercan; Meral Sakizli
Journal:  Genet Test Mol Biomarkers       Date:  2015-04-15

4.  A peptide interfering with the dimerization of oncogenic KITENIN protein and its stability suppresses colorectal tumour progression.

Authors:  Sung Jin Kim; Eun Gene Sun; Jeong A Bae; Sehoon Park; Chang-Soo Hong; Zee-Yong Park; Hangun Kim; Kyung Keun Kim
Journal:  Clin Transl Med       Date:  2022-07

Review 5.  Vangl as a Master Scaffold for Wnt/Planar Cell Polarity Signaling in Development and Disease.

Authors:  Courtney A Dreyer; Kacey VanderVorst; Kermit L Carraway
Journal:  Front Cell Dev Biol       Date:  2022-05-11

6.  A new KSRP-binding compound suppresses distant metastasis of colorectal cancer by targeting the oncogenic KITENIN complex.

Authors:  Jeong A Bae; Woo Kyun Bae; Sung Jin Kim; Yoo-Seung Ko; Keon Young Kim; So-Yeon Park; Young Hyun Yu; Eun Ae Kim; Ik Joo Chung; Hangun Kim; Hyung-Ho Ha; Kyung Keun Kim
Journal:  Mol Cancer       Date:  2021-05-26       Impact factor: 27.401

7.  KITENIN promotes glioma invasiveness and progression, associated with the induction of EMT and stemness markers.

Authors:  Kyung-Hwa Lee; Eun-Jung Ahn; Se-Jeong Oh; Ok Kim; Young-Eun Joo; Jeong-A Bae; Somy Yoon; Hyang-Hwa Ryu; Shin Jung; Kyung-Keun Kim; Jae-Hyuk Lee; Kyung-Sub Moon
Journal:  Oncotarget       Date:  2015-02-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.